In the bio-tech sector,
Merck & Co., Inc. (NYSE:MRK) has gained significant attention from investors, asset managers, and financial advisors. Merck's stock has shown some volatility but several factors point towards a strong fundamental base. Multiple institutions such as Symphony Financial, Costello Asset Management, and Heck Capital Advisors have recently purchased shares, indicating an increasing interest. Despite falling 9% in three months, the stock is considered a good buy as well as an attractive investment option under $100. Several robust features of Merck’s stock, namely being a steady source of dividends, having a healthy balance sheet, potential acquisition news, and being a potential good choice for beginners make it appealing.
Billionaire D.E. Shaw is bullish on Merck, further exemplifying its potential attractiveness. The stock trades near its 52-week low, while its fundamentals remain strong. It is posed as one of the best defensive stocks as per Reddit and also marked as one of the best low volatility stocks to invest in. Popular TV personality
Jim Cramer has offered varying views about Merck’s current trade. Notably, Merck holds a strong institutional backing, with 79% ownership.
Merck Stocks MRK News Analytics from Thu, 01 Aug 2024 07:00:00 GMT to Sat, 01 Feb 2025 21:44:08 GMT -
